Amouyal Philippe 4

What Happened

• Philippe, a director of Lexicon Pharmaceuticals, received two equity awards on 2026-05-01: 35,714 and 43,478 restricted stock units (RSUs), both reported as derivative acquisitions at $0.00. Total award = 79,192 RSUs. These are grants (compensation), not open-market purchases or sales.

Key Details

• Transaction date: 2026-05-01; filing date: 2026-05-04 (Form 4 accession 0001062822-26-000092).
• Award amounts/prices: 35,714 RSUs @ $0.00 and 43,478 RSUs @ $0.00 (total 79,192 RSUs); reported value shown as $0 because no cash was paid at grant.
• Vesting: Per footnote F1, 100% of each RSU vests on the first anniversary of the grant date. Per F2, each RSU represents a contingent right to one share of common stock.
• Shares owned after transaction: not disclosed in the provided details.
• Filing timeliness: filed a few days after the grant date; appears to be timely based on the reported dates.
• Note: footnote F3 (option vesting schedule) was included in the filing materials but does not apply to these RSU awards.

Context

• RSUs are a form of compensation that convert into actual shares only upon vesting; there was no exercise or sale involved and no immediate cash proceeds. These grants increase potential future share issuance if and when they vest; they are not a direct buy/sell signal.